title: Kinesin inhibitor marches toward first-in-class pivotal trial.
authors.forename: Brian
authors.initials: B
authors.lastname: Owens
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D054316:Biomarkers, Pharmacological / Q000032:analysis; D002986:Clinical Trials as Topic; D006801:Humans; D016547:Kinesins / Q000037:antagonists & inhibitors* / Q000502:physiology; D058990:Molecular Targeted Therapy / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects; D013830:Thiadiazoles / Q000627:therapeutic use*; D050257:Tubulin Modulators / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D054316:Biomarkers, Pharmacological; C470243:KIF11 protein, human; D013830:Thiadiazoles; D050257:Tubulin Modulators; C544550:filanesib; D016547:Kinesins